Review



recombinant mouse tissue factor pathway inhibitor  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    R&D Systems recombinant mouse tissue factor pathway inhibitor
    Effect of angiogenesis inhibitors on bone marrow cells from female C57BL/6N mice. (a) Schematic illustration of ex‐vivo experimental design. (b) Effect of pazopanib (VEGF inhibitor) on the inhibition of tEVs‐induced bone marrow cell proliferation. (c) Effect of pioglitazone (osteopontin inhibitor) on the inhibition of tEVs‐induced bone marrow cell proliferation. (d) Effect of epicatechin (ADAMTS‐1 inhibitor) on the inhibition of tEVs‐induced bone marrow cell proliferation. (e) Effect of rmTFPI (tissue factor pathway inhibitor) on the inhibition tEVs‐induced bone marrow cell proliferation. The cells were treated either inhibitors alone or with inhibitors in combination with 5e9 tEVs. The data are presented as means (±SD, n = 3). Statistical significance (* p < 0.01, *** p < 0.001, and **** p < 0.0001) between experimental groups was calculated with using one‐way analysis of variance (ANOVA) with each value Tukey's multiple comparisons test.
    Recombinant Mouse Tissue Factor Pathway Inhibitor, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+tissue+factor+pathway+inhibitor/pmc11214607-139-29-36?v=R%26D+Systems
    Average 92 stars, based on 4 article reviews
    recombinant mouse tissue factor pathway inhibitor - by Bioz Stars, 2026-07
    92/100 stars

    Images

    1) Product Images from "Extracellular vesicles originating from melanoma cells promote dysregulation in haematopoiesis as a component of cancer immunoediting"

    Article Title: Extracellular vesicles originating from melanoma cells promote dysregulation in haematopoiesis as a component of cancer immunoediting

    Journal: Journal of Extracellular Vesicles

    doi: 10.1002/jev2.12471

    Effect of angiogenesis inhibitors on bone marrow cells from female C57BL/6N mice. (a) Schematic illustration of ex‐vivo experimental design. (b) Effect of pazopanib (VEGF inhibitor) on the inhibition of tEVs‐induced bone marrow cell proliferation. (c) Effect of pioglitazone (osteopontin inhibitor) on the inhibition of tEVs‐induced bone marrow cell proliferation. (d) Effect of epicatechin (ADAMTS‐1 inhibitor) on the inhibition of tEVs‐induced bone marrow cell proliferation. (e) Effect of rmTFPI (tissue factor pathway inhibitor) on the inhibition tEVs‐induced bone marrow cell proliferation. The cells were treated either inhibitors alone or with inhibitors in combination with 5e9 tEVs. The data are presented as means (±SD, n = 3). Statistical significance (* p < 0.01, *** p < 0.001, and **** p < 0.0001) between experimental groups was calculated with using one‐way analysis of variance (ANOVA) with each value Tukey's multiple comparisons test.
    Figure Legend Snippet: Effect of angiogenesis inhibitors on bone marrow cells from female C57BL/6N mice. (a) Schematic illustration of ex‐vivo experimental design. (b) Effect of pazopanib (VEGF inhibitor) on the inhibition of tEVs‐induced bone marrow cell proliferation. (c) Effect of pioglitazone (osteopontin inhibitor) on the inhibition of tEVs‐induced bone marrow cell proliferation. (d) Effect of epicatechin (ADAMTS‐1 inhibitor) on the inhibition of tEVs‐induced bone marrow cell proliferation. (e) Effect of rmTFPI (tissue factor pathway inhibitor) on the inhibition tEVs‐induced bone marrow cell proliferation. The cells were treated either inhibitors alone or with inhibitors in combination with 5e9 tEVs. The data are presented as means (±SD, n = 3). Statistical significance (* p < 0.01, *** p < 0.001, and **** p < 0.0001) between experimental groups was calculated with using one‐way analysis of variance (ANOVA) with each value Tukey's multiple comparisons test.

    Techniques Used: Ex Vivo, Inhibition



    Similar Products

    recombinant mouse tissue factor pathway inhibitor  (R&D Systems)
    92
    R&D Systems recombinant mouse tissue factor pathway inhibitor
    Effect of angiogenesis inhibitors on bone marrow cells from female C57BL/6N mice. (a) Schematic illustration of ex‐vivo experimental design. (b) Effect of pazopanib (VEGF inhibitor) on the inhibition of tEVs‐induced bone marrow cell proliferation. (c) Effect of pioglitazone (osteopontin inhibitor) on the inhibition of tEVs‐induced bone marrow cell proliferation. (d) Effect of epicatechin (ADAMTS‐1 inhibitor) on the inhibition of tEVs‐induced bone marrow cell proliferation. (e) Effect of rmTFPI (tissue factor pathway inhibitor) on the inhibition tEVs‐induced bone marrow cell proliferation. The cells were treated either inhibitors alone or with inhibitors in combination with 5e9 tEVs. The data are presented as means (±SD, n = 3). Statistical significance (* p < 0.01, *** p < 0.001, and **** p < 0.0001) between experimental groups was calculated with using one‐way analysis of variance (ANOVA) with each value Tukey's multiple comparisons test.
    Recombinant Mouse Tissue Factor Pathway Inhibitor, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+tissue+factor+pathway+inhibitor/pmc11214607-139-29-36?v=R%26D+Systems
    Average 92 stars, based on 1 article reviews
    recombinant mouse tissue factor pathway inhibitor - by Bioz Stars, 2026-07
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    Effect of angiogenesis inhibitors on bone marrow cells from female C57BL/6N mice. (a) Schematic illustration of ex‐vivo experimental design. (b) Effect of pazopanib (VEGF inhibitor) on the inhibition of tEVs‐induced bone marrow cell proliferation. (c) Effect of pioglitazone (osteopontin inhibitor) on the inhibition of tEVs‐induced bone marrow cell proliferation. (d) Effect of epicatechin (ADAMTS‐1 inhibitor) on the inhibition of tEVs‐induced bone marrow cell proliferation. (e) Effect of rmTFPI (tissue factor pathway inhibitor) on the inhibition tEVs‐induced bone marrow cell proliferation. The cells were treated either inhibitors alone or with inhibitors in combination with 5e9 tEVs. The data are presented as means (±SD, n = 3). Statistical significance (* p < 0.01, *** p < 0.001, and **** p < 0.0001) between experimental groups was calculated with using one‐way analysis of variance (ANOVA) with each value Tukey's multiple comparisons test.

    Journal: Journal of Extracellular Vesicles

    Article Title: Extracellular vesicles originating from melanoma cells promote dysregulation in haematopoiesis as a component of cancer immunoediting

    doi: 10.1002/jev2.12471

    Figure Lengend Snippet: Effect of angiogenesis inhibitors on bone marrow cells from female C57BL/6N mice. (a) Schematic illustration of ex‐vivo experimental design. (b) Effect of pazopanib (VEGF inhibitor) on the inhibition of tEVs‐induced bone marrow cell proliferation. (c) Effect of pioglitazone (osteopontin inhibitor) on the inhibition of tEVs‐induced bone marrow cell proliferation. (d) Effect of epicatechin (ADAMTS‐1 inhibitor) on the inhibition of tEVs‐induced bone marrow cell proliferation. (e) Effect of rmTFPI (tissue factor pathway inhibitor) on the inhibition tEVs‐induced bone marrow cell proliferation. The cells were treated either inhibitors alone or with inhibitors in combination with 5e9 tEVs. The data are presented as means (±SD, n = 3). Statistical significance (* p < 0.01, *** p < 0.001, and **** p < 0.0001) between experimental groups was calculated with using one‐way analysis of variance (ANOVA) with each value Tukey's multiple comparisons test.

    Article Snippet: The inhibitory effect of pazopanib, a VEGFR inhibitor (SML3076, Sigma‐Aldrich, Germany), pioglitazone, an osteopontin inhibitor (E6910, Sigma‐Aldrich, Germany), epigallocatechin, an ADAMTS‐1 inhibitor (E3768, Sigma‐Aldrich, Germany), and rmTFPI Protein, a recombinant mouse tissue factor pathway inhibitor (2975‐PI, R&D Systems) were evaluated to assess their abilities to prevent the possible impact of tEVs on the hematopoietic.

    Techniques: Ex Vivo, Inhibition